Inhibition of Niemann-Pick C1-Like 1 by Ezetimibe Reduces Dietary 5β,6β-Epoxycholesterol Absorption in Rats

Bungo Shirouchi, Yumiko Furukawa, Yuri Nakamura, Asuka Kawauchi, Katsumi Imaizumi, Hirosuke Oku, Masao Sato

Research output: Contribution to journalArticle

Abstract

Purpose: Oxycholesterols (OCs) are produced from cholesterol by oxidation of the steroidal backbone and side-chain. OCs are present in blood and evidence suggests their involvement in disease development and progression. However, limited information is available regarding the absorption mechanisms and relative absorption rates of dietary OCs. Although ezetimibe is known to inhibit intestinal cholesterol absorption via Niemann-Pick C1-Like 1 (NPC1L1), whether it also inhibits dietary OC absorption is unclear. Methods: We investigated the effects of ezetimibe on OC absorption in rats fed an OC-rich diet containing 10 different OCs. We collected lymphatic fluid using permanent cannulation of the thoracic duct and quantified OC levels. Results: Ezetimibe treatment significantly reduced the apparent absorption of 5β,6β-epoxycholesterol (5,6β-epoxy) and its levels in the proximal intestinal mucosa in OC-fed rats. Using in silico analyses, the binding energy of NPC1L1 N-terminal domain (NPC1L1-NTD) and 5,6β-epoxy was found to be similar to that of NPC1L1-NTD and cholesterol, suggesting that polar uncharged amino acids located in the steroidal part of 5,6β-epoxy were involved. Conclusion: Our results indicate that ezetimibe-mediated inhibition of dietary OC absorption varies depending on the specific OC, and only the absorption of 5,6β-epoxy is significantly reduced.

Original languageEnglish
Pages (from-to)35-44
Number of pages10
JournalCardiovascular Drugs and Therapy
Volume33
Issue number1
DOIs
Publication statusPublished - Feb 15 2019

Fingerprint

Cholesterol
Thoracic Duct
Intestinal Absorption
Intestinal Mucosa
5,6-epoxycholesterol
Ezetimibe
Catheterization
Computer Simulation
Disease Progression
Diet
Amino Acids
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Inhibition of Niemann-Pick C1-Like 1 by Ezetimibe Reduces Dietary 5β,6β-Epoxycholesterol Absorption in Rats. / Shirouchi, Bungo; Furukawa, Yumiko; Nakamura, Yuri; Kawauchi, Asuka; Imaizumi, Katsumi; Oku, Hirosuke; Sato, Masao.

In: Cardiovascular Drugs and Therapy, Vol. 33, No. 1, 15.02.2019, p. 35-44.

Research output: Contribution to journalArticle

Shirouchi, Bungo ; Furukawa, Yumiko ; Nakamura, Yuri ; Kawauchi, Asuka ; Imaizumi, Katsumi ; Oku, Hirosuke ; Sato, Masao. / Inhibition of Niemann-Pick C1-Like 1 by Ezetimibe Reduces Dietary 5β,6β-Epoxycholesterol Absorption in Rats. In: Cardiovascular Drugs and Therapy. 2019 ; Vol. 33, No. 1. pp. 35-44.
@article{e8d26d0bfd98459a8ac4447442ec07f7,
title = "Inhibition of Niemann-Pick C1-Like 1 by Ezetimibe Reduces Dietary 5β,6β-Epoxycholesterol Absorption in Rats",
abstract = "Purpose: Oxycholesterols (OCs) are produced from cholesterol by oxidation of the steroidal backbone and side-chain. OCs are present in blood and evidence suggests their involvement in disease development and progression. However, limited information is available regarding the absorption mechanisms and relative absorption rates of dietary OCs. Although ezetimibe is known to inhibit intestinal cholesterol absorption via Niemann-Pick C1-Like 1 (NPC1L1), whether it also inhibits dietary OC absorption is unclear. Methods: We investigated the effects of ezetimibe on OC absorption in rats fed an OC-rich diet containing 10 different OCs. We collected lymphatic fluid using permanent cannulation of the thoracic duct and quantified OC levels. Results: Ezetimibe treatment significantly reduced the apparent absorption of 5β,6β-epoxycholesterol (5,6β-epoxy) and its levels in the proximal intestinal mucosa in OC-fed rats. Using in silico analyses, the binding energy of NPC1L1 N-terminal domain (NPC1L1-NTD) and 5,6β-epoxy was found to be similar to that of NPC1L1-NTD and cholesterol, suggesting that polar uncharged amino acids located in the steroidal part of 5,6β-epoxy were involved. Conclusion: Our results indicate that ezetimibe-mediated inhibition of dietary OC absorption varies depending on the specific OC, and only the absorption of 5,6β-epoxy is significantly reduced.",
author = "Bungo Shirouchi and Yumiko Furukawa and Yuri Nakamura and Asuka Kawauchi and Katsumi Imaizumi and Hirosuke Oku and Masao Sato",
year = "2019",
month = "2",
day = "15",
doi = "10.1007/s10557-019-06854-4",
language = "English",
volume = "33",
pages = "35--44",
journal = "Cardiovascular Drugs and Therapy",
issn = "0920-3206",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Inhibition of Niemann-Pick C1-Like 1 by Ezetimibe Reduces Dietary 5β,6β-Epoxycholesterol Absorption in Rats

AU - Shirouchi, Bungo

AU - Furukawa, Yumiko

AU - Nakamura, Yuri

AU - Kawauchi, Asuka

AU - Imaizumi, Katsumi

AU - Oku, Hirosuke

AU - Sato, Masao

PY - 2019/2/15

Y1 - 2019/2/15

N2 - Purpose: Oxycholesterols (OCs) are produced from cholesterol by oxidation of the steroidal backbone and side-chain. OCs are present in blood and evidence suggests their involvement in disease development and progression. However, limited information is available regarding the absorption mechanisms and relative absorption rates of dietary OCs. Although ezetimibe is known to inhibit intestinal cholesterol absorption via Niemann-Pick C1-Like 1 (NPC1L1), whether it also inhibits dietary OC absorption is unclear. Methods: We investigated the effects of ezetimibe on OC absorption in rats fed an OC-rich diet containing 10 different OCs. We collected lymphatic fluid using permanent cannulation of the thoracic duct and quantified OC levels. Results: Ezetimibe treatment significantly reduced the apparent absorption of 5β,6β-epoxycholesterol (5,6β-epoxy) and its levels in the proximal intestinal mucosa in OC-fed rats. Using in silico analyses, the binding energy of NPC1L1 N-terminal domain (NPC1L1-NTD) and 5,6β-epoxy was found to be similar to that of NPC1L1-NTD and cholesterol, suggesting that polar uncharged amino acids located in the steroidal part of 5,6β-epoxy were involved. Conclusion: Our results indicate that ezetimibe-mediated inhibition of dietary OC absorption varies depending on the specific OC, and only the absorption of 5,6β-epoxy is significantly reduced.

AB - Purpose: Oxycholesterols (OCs) are produced from cholesterol by oxidation of the steroidal backbone and side-chain. OCs are present in blood and evidence suggests their involvement in disease development and progression. However, limited information is available regarding the absorption mechanisms and relative absorption rates of dietary OCs. Although ezetimibe is known to inhibit intestinal cholesterol absorption via Niemann-Pick C1-Like 1 (NPC1L1), whether it also inhibits dietary OC absorption is unclear. Methods: We investigated the effects of ezetimibe on OC absorption in rats fed an OC-rich diet containing 10 different OCs. We collected lymphatic fluid using permanent cannulation of the thoracic duct and quantified OC levels. Results: Ezetimibe treatment significantly reduced the apparent absorption of 5β,6β-epoxycholesterol (5,6β-epoxy) and its levels in the proximal intestinal mucosa in OC-fed rats. Using in silico analyses, the binding energy of NPC1L1 N-terminal domain (NPC1L1-NTD) and 5,6β-epoxy was found to be similar to that of NPC1L1-NTD and cholesterol, suggesting that polar uncharged amino acids located in the steroidal part of 5,6β-epoxy were involved. Conclusion: Our results indicate that ezetimibe-mediated inhibition of dietary OC absorption varies depending on the specific OC, and only the absorption of 5,6β-epoxy is significantly reduced.

UR - http://www.scopus.com/inward/record.url?scp=85060548269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060548269&partnerID=8YFLogxK

U2 - 10.1007/s10557-019-06854-4

DO - 10.1007/s10557-019-06854-4

M3 - Article

C2 - 30671747

AN - SCOPUS:85060548269

VL - 33

SP - 35

EP - 44

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - 1

ER -